Glaxosmithkline

This early-stage study is testing a new mRNA vaccine that aims to protect against both seasonal flu and COVID-19 with a single shot. Around 1,475 healthy adults aged 65 to 85 will receive either the new combo vaccine, a standard flu vaccine, or a licensed COVID-19 vaccine. Resear…

This study tests a new chickenpox vaccine in 600 healthy toddlers aged 12-15 months. The children receive two doses, and the new vaccine is compared to the current standard, Varivax. The goal is to see if the new vaccine produces a strong immune response and is safe.

This study tests a new chickenpox vaccine in 750 healthy children aged 12-15 months. Researchers will compare its safety to the existing Varivax vaccine. The goal is to see if the new vaccine causes similar side effects like injection site pain, fever, or rash.

This study tests a new chickenpox vaccine given as a muscle injection in healthy children aged 12 to 15 months. It compares the immune response and safety of this vaccine to the standard shot given under the skin. The study also looks at combining it with the MMR vaccine. About 9…

This study tests a new chickenpox vaccine in healthy children aged 12 to 15 months who have never had chickenpox or the vaccine. Researchers want to see if the new vaccine works as well as the approved Varivax vaccine and if different batches of the new vaccine produce consistent…

This study tests a single dose of an experimental RSV vaccine in Chinese adults aged 18 to 59 who have health conditions that raise their risk for severe RSV disease. Researchers will compare their immune response to that of older adults (60+) from a previous study. The trial als…

This study tests a new vaccine designed to prevent urinary tract infections (UTIs) caused by E. coli bacteria. Researchers will check safety and immune response in 448 adults aged 18-64, and then see if it works in women of the same age. Participants receive either the vaccine or…

This study is testing a new vaccine called iNTS-TCV in 537 infants in Africa. The vaccine is designed to protect against two serious bacterial infections: invasive nontyphoidal salmonella (iNTS) and typhoid fever. Researchers are giving the vaccine to infants starting at either 6…

This study looks at how well an RSV vaccine works and how safe it is in adults who have had a lung or kidney transplant. About 184 participants will receive the vaccine to see if their immune response lasts and if a booster dose is safe. The goal is to help protect transplant rec…

This study is testing a new shingles vaccine (PED-HZ/su) in children aged 1 to 17 who have had a kidney transplant and have weakened immune systems. The vaccine is given as two shots in the arm. Researchers are checking how safe it is, what side effects occur, and how well it boo…

This study is testing whether giving the RTS,S/AS01E malaria vaccine (Mosquirix) in lower doses or on different schedules is safe and triggers a strong immune response in healthy children aged 5 months to 5 years. The goal is to find simpler ways to vaccinate children in areas wh…

This study tests whether a new propellant (HFA-152a) in salbutamol inhalers works as well as the current one (HFA-134a) for people with mild asthma. 84 adults aged 18-65 will receive single doses of the inhaler or a placebo. The main goal is to measure how well the inhaler protec…

This study tests whether depemokimab, an injected biologic drug, can reduce severe asthma attacks and help patients achieve remission when added to standard care. About 456 adults and adolescents with type 2 asthma at risk of flare-ups will receive either depemokimab or a placebo…

This study offers continued access to niraparib, a daily oral cancer drug, for up to 37 patients with ovarian or breast cancer who have already completed a prior niraparib trial and are still benefiting. The main goal is to monitor long-term safety, including side effects and cha…

This early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…

This study tests whether giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control multiple myeloma while reducing side effects like eye problems. About 200 adults whose cancer has returned or stopped responding to prior tre…

This study tests a new drug called GSK3862995B in 446 adults with bronchiectasis, a long-term lung condition. The goal is to see if the drug can reduce the number of serious lung infections (exacerbations) compared to a placebo. Participants will receive either one of two doses o…

This study tests a new drug, IDRX-42, against the current standard drug sunitinib in adults with advanced gastrointestinal stromal tumors (GIST) that have spread or can't be removed by surgery and have already been treated with imatinib. About 450 participants will be randomly as…

This study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …

This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes who have anemia. The goal is to see if it can help them need fewer red blood cell transfusions. Participants will receive different doses to find the safest and most effective one.

This study tests whether the drug dostarlimab, given after standard chemoradiation, can help prevent head and neck cancer from coming back or spreading. About 864 adults with advanced but not surgically removable head and neck cancer will receive either dostarlimab or a placebo. …

This study tests a new medicine called Risvutatug rezetecan (Ris-Rez) that targets a specific protein (B7-H3) on cancer cells to stop their growth. It is for adults with relapsed small cell lung cancer who have already tried one prior treatment. About 420 participants will be ran…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This study tests a drug called belantamab, given alone or with other treatments, in people with multiple myeloma. The trial has three parts: first, finding a safe dose; second, testing combinations; third, comparing the best option to standard care. About 152 participants will be…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (CAPEOX) before surgery works better than chemotherapy alone for a common type of colon cancer (MMRp/MSS). About 120 people with stage III or T4N0 colon cancer that has not been treated ye…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This study tests a drug called depemokimab in 150 adults with severe asthma caused by a specific type of inflammation. The goal is to see if the drug can reduce mucus plugs and airway thickening in the lungs. Participants will receive the drug and have lung scans and breathing te…

This Phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, lenalidomide, and dexamethasone—can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The study will compare this new combo to the current standard treatment …

This phase 2 study tests whether combining two drugs, momelotinib and luspatercept, can help people with myelofibrosis who need regular blood transfusions. About 68 adults with primary or secondary myelofibrosis will receive the combination orally or by injection. The main goal i…

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver hea…

This Phase 3 trial tests whether efimosfermin alfa can improve liver scarring and reduce inflammation in people with MASH (a type of fatty liver disease). About 1,200 adults with moderate-to-severe liver fibrosis will receive the drug or a placebo for 52 weeks. The goal is to see…

This study tests an experimental drug called depemokimab in adults aged 40 to 80 with moderate to severe COPD and type 2 inflammation. The goal is to see if adding this medicine to standard care can reduce the number of serious flare-ups that require steroids, antibiotics, or hos…

This study tests a new drug, GSK4532990, in about 393 adults with liver inflammation from alcohol use. The goal is to see if it safely reduces liver stiffness and improves liver function over 52 weeks. Participants receive either the drug or a placebo, and researchers monitor sid…

This phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…

This study is an extension of an earlier trial, testing the long-term safety and effectiveness of the drug GSK4527226 in people with early Alzheimer's disease (mild cognitive impairment or mild dementia). All 220 participants will receive the drug, and researchers will monitor fo…

This phase 3 trial tests the immunotherapy drug dostarlimab against standard chemotherapy in 892 people with a specific type of colon cancer (dMMR/MSI-H) that has not spread. The goal is to see if dostarlimab alone can prevent cancer from coming back or causing death. Participant…

This study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…

This study tests a new medicine, GSK5764227, that delivers a toxin directly to cancer cells to destroy them while leaving healthy cells alone. It is given together with standard treatments to people with advanced solid tumors like colorectal or prostate cancer. The main goals are…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab, given together with standard chemotherapy (carboplatin and paclitaxel), can help Chinese patients with a specific genetic type of advanced or recurrent endometrial cancer. The study will enroll 30 participa…

This study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to severa…

This study tests whether adding depemokimab early to standard COPD treatment can reduce moderate to severe flare-ups in people with moderate to severe COPD who have type 2 inflammation. About 1,200 participants will receive either depemokimab or a placebo as an add-on therapy. Th…

This study tests a drug called depemokimab in adults with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause organ damage. The trial includes 123 people whose HES is not well controlled despite standard therapy. Partic…

This study tests an experimental drug called GSK5764227, given alone or with other treatments, in 320 people with advanced gastrointestinal cancers that have not responded to prior therapy. The main goal is to see if the drug can shrink tumors and how safe it is. It is an early-s…

This study tests whether a triple-combination inhaler (containing three drugs) works better than a standard dual-combination inhaler for teenagers aged 12-17 whose asthma is not well controlled. About 292 participants will use either the triple or dual inhaler daily for 24 weeks.…

This study tests an experimental drug called depemokimab for people with moderate to severe COPD who also have type 2 inflammation. The goal is to see if adding this medicine to standard treatment can reduce the number of serious flare-ups that require steroids, antibiotics, or h…

This study is testing whether the Shingrix vaccine, already used to prevent shingles, can also lower the risk of dementia in adults aged 76 and older. Over 33,000 participants in Finland will receive either the vaccine or a placebo. Researchers will track new dementia diagnoses o…

This Phase 2b study tests camlipixant, an experimental drug, in 420 adults with moderate-to-severe irritable bowel syndrome (IBS) with diarrhea or mixed bowel habits. Participants receive either camlipixant or a placebo for 26 weeks. The main goal is to see if the drug reduces we…

This study tests an experimental drug called BLU-5937 in adults who have had a stubborn cough for at least a year that hasn't improved with other treatments. About 75 people in China will receive either the drug or a placebo for 24 weeks to see if it reduces coughing and is safe.…

This early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

This early-stage study tests a single dose of the experimental drug efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the body processes the drug, and immune reactions. Participants will not receive any trea…

This study follows 300 adults with lupus nephritis who are already taking belimumab as part of their routine care. Researchers will track kidney function for up to 5 years to see how well the drug preserves renal health and prevents the need for dialysis or transplant. The goal i…

This study is testing whether special lab tools—like analyzing tiny particles from blood cells or growing mini-tumors in a dish—can predict how well immunotherapy drugs work in people whose lung cancer has returned. About 40 participants will receive standard immunotherapy drugs …